Skip to content

A Prospective, Cohort Trial for the Total Hysterectomy + Sentinel Lymph Node Dissection Surgery by vNOTES Treatment for Stage I Endometrial Carcinoma

A Prospective, Cohort Trial for the Total Hysterectomy + Sentinel Lymph Node Dissection Surgery by vNOTES Treatment for Stage I Endometrial Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040011
Enrollment
Unknown
Registered
2020-11-18
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial carcinoma

Interventions

Sponsors

Cancer Hospital Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients with histopathologically confirmed primary endometrioid carcinoma; 2. According to the preoperative pathological results and imaging findings, patients with stage I, low and medium risk endometrial cancer were included; 3. Patients who underwent total bilateral hysterectomy and sentinel lymph node biopsy; 4. Patients with normal bone marrow, kidney and liver function; 5. Patients who have signed the approved informed consent; 6. Patients without history of other malignancies in the past 5 years; 7. Female of 18 years old or older.

Exclusion criteria

Exclusion criteria: 1. Preoperative pathology reported any other histology other than endometrial carcinoma; 2. Patients with high-risk endometrial cancer; 3. Conventional imaging studies showed pelvic or aortic lymph node metastases or histologically confirmed lymph nodes metastases; 4. Patients with a history of pelvic or abdominal radiation therapy; 5. Ultrasound indicated that the uterine maximum diameter line was greater than 12cm; 6. Patients with contraindications to surgery, or with severe systemic disease; 7. Patients cannot withstand prolonged lithotomy position; 8. Patients with poor compliance or far from adequate follow-up.

Design outcomes

Primary

MeasureTime frame
operative time;detection rate of sentinel lymph node;bleeding volume;VAS score;length of hospital stay;intraoperative complications;postoperative complications;recurrence time;

Countries

China

Contacts

Public ContactLi Sun

Cancer Hospital Chinese Academy of Medical Sciences

xjsunli@sina.com+86 13520594695

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026